Dyadic International (NASDAQ:DYAI) Announces Earnings Results

Dyadic International (NASDAQ:DYAIGet Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01), Zacks reports. The business had revenue of $0.82 million during the quarter, compared to the consensus estimate of $1.60 million. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. During the same period last year, the firm earned ($0.24) EPS.

Dyadic International Trading Up 1.5 %

DYAI stock opened at $1.35 on Friday. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.54. The firm has a market cap of $39.95 million, a P/E ratio of -5.87 and a beta of 0.95. Dyadic International has a 1-year low of $0.93 and a 1-year high of $2.67. The business’s 50 day moving average is $1.47 and its 200-day moving average is $1.42.

Institutional Trading of Dyadic International

A hedge fund recently raised its stake in Dyadic International stock. Bank of America Corp DE grew its position in Dyadic International, Inc. (NASDAQ:DYAIFree Report) by 16,146.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,132 shares of the biotechnology company’s stock after purchasing an additional 26,965 shares during the period. Bank of America Corp DE owned about 0.09% of Dyadic International worth $47,000 as of its most recent filing with the SEC. Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

(Get Free Report)

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.

Further Reading

Earnings History for Dyadic International (NASDAQ:DYAI)

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.